FDA says Fuyang Fuchunjiang under-processed 230g roasted gluten pouches and lacked retort flow/temperature records.
What happened
FDA inspected the facility from March 11 to March 13, 2024, and issued a Form FDA-483, a list of inspection observations. Batch records showed retort cycles with more 230g roasted gluten pouches than the studies supported, which may have left exported batches under-processed, and the retort lacked a water-flow meter and continuous temperature records. FDA received the company’s response on March 30, 2024.
What FDA found
The firm did not process 230g roasted gluten in conformity with its required heat process; its studies did not record total pouches per retort cycle, and batch records showed cycles with more pouches than supported.
21 CFR 108.35(c)(3)(i)The firm did not measure the retort’s minimum water flow rate, a critical factor in the required heat process, and had no records showing the required flow was delivered.
21 CFR 113.40(j)The firm did not have continuous temperature recording chart data for the retort and documented processing temperature only once per batch after installing a recorder.
21 CFR 113.40(j)FDA commented that the firm relies on visual pouch inspection, does not document discarded packages, and does not perform destructive seal tests, despite U.S. complaints of damaged seams.
21 CFR 113.60(a)(2)
What FDA wants
FDA asks the company to respond in writing within 15 working days with corrective actions and documentation. It also asks the firm to evaluate all U.S. lots of 230g roasted gluten within shelf life made before March 30, 2024 to ensure they are commercially sterile and to say whether it will take market action.
Who should pay attention
- U.S. importers and distributors of roasted gluten pouches
- brands selling shelf-stable low-acid canned foods
- retort operators and contract processors of pouch foods
This is a summary. Read the original letter on fda.gov.